SNT - Broker DATA, page-64

Certainly not referencing SNT or even your posts , mainly reference to PLatinum and Hartley's regarding fraudulent valuations etc

I've been in Biotech for over 25 years ,, I'm comfortable with my investments especially here at SNT...

MC valuation has always been low for a multi Phase II Candidate Company .. really SNT picked up the IP silverware from PXS , for me considerable risk has been removed when reading the ANZCTR Trial Register and the NIH Study parameters and Trial Updates..

The Data will do the talking ,,, after all that's where the Value lays in this game.. NZT